| Patient 1 | Patient 2 | Patient 3 | |
| Sex/age (years) | F/29 | F/30 | F/29 |
| Disease duration (years) | 27 | 18 | 22 |
| Previous treatments | Anakinra, AZA, CsA, ETA, GS, IG, MTX | Anakinra, CQ, ETA, GS, IFX, LF, MTX | Anakinra, ADM, CsA, DP, GS, IFX, IG, LF, MTX, SSZ |
| Main symptoms at RTX treatment initiation | Fever, rash, arthritis, pleuritis, pericarditis | Fever, rash, arthritis | Fever, rash, arthritis |
| ESR (mm/h)/CRP (mg/l) | 75/171 | 104/258 | 64/128 |
| TJC 28/SJC 28 | 9/5 | 25/24 | 11/6 |
| DAS28 | 6.31 | 8.68 | 6.43 |
| Dose of prednisone (mg/day) | 30 | 10 | 30 |
| Concomitant treatment associated with RTX | MTX 15 mg/week | MTX 15 mg/week | None |
| Outcome | |||
| Response at month 6 | Remission of systemic symptoms | Remission of systemic symptoms | Remission of systemic symptoms |
| ESR 81/CRP 143 | ESR 67/CRP 180 | ESR 40/CRP 32 | |
| TJC 28 4/SJC 28 1 | TJC 28 6/SJC 28 6 | TJC 28 1/SJC 28 0 | |
| DAS28 4.62 | DAS28 5.70 | DAS28 3.28 | |
| Re-treatment: Yes | Re-treatment: Yes | Re-treatment: No | |
| (severe hypersensitivity reaction during 2nd infusion) | |||
| Response at 1 year | Remission of systemic symptoms | Remission of systemic symptoms | Remission of systemic symptoms |
| ESR 53/CRP 94 | ESR 65/CRP 141 | ESR 44/CRP 47 | |
| TJC 28 5/SJC 28 2 | TJC 28 7/SJC 28 5 | TJC 28 3/SJC 28 2 | |
| DAS28 5.20 | DAS28 5.59 | DAS28 4.57 | |
| Re-treatment: Yes | Re-treatment: Yes | ||
| Comments | Prednisone daily dosage reduced to 10 mg | Prednisone daily dosage reduced to 5 mg | Prednisone daily dosage reduced to 5 mg |
ADM, adalimumab; AZA, azathioprine; CQ, chloroquine; CRP, C-reactive protein; CsA, ciclosporin A; DAS28, disease activity score in 28 joints; DP, D-penicillamine; ESR, erythrocyte sedimentation rate; ETA, etanercept; GS, gold salts; IG, intravenous polyvalent immunoglobulin; IFX, infliximab; LF, leflunomide; MTX, methotrexate; RTX, rituximab; SJC, swollen joint count; SSZ, sulfasalazine; TJC, tender joint count.